anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
CUL4A is an ubiquitin ligase deregulated in numerous pathologies including cancer and even hijacked by viruses for facilitating their survival and propagation. However, its role in Human papilloma virus (HPV)-mediated cervical carcinogenesis remains elusive. The UALCAN and GEPIA datasets were analyzed to ascertain the transcript levels of CUL4A in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) patients. Subsequently, various biochemical assays were employed to explore the functional contribution of CUL4A in cervical carcinogenesis and to shed some light on its involvement in Cisplatin resistance in cervical cancer. Our UALCAN and GEPIA datasets analyses reveal elevated CUL4A transcript levels in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) patients that correlate with adverse clinicopathological parameters such as tumor stage and lymph node metastasis. Kaplan-Meier plot and GEPIA assessment depict poor prognosis of CESC patients having high CUL4A expression. Varied biochemical assays illustrate that CUL4A inhibition severely curtails hallmark malignant properties such as cellular proliferation, migration, and invasion of cervical cancer cells. We also show that CUL4A knockdown in HeLa cells causes increased susceptibility and better apoptotic induction toward Cisplatin, a mainstay drug used in cervical cancer treatment. More interestingly, we find reversion of Cisplatin-resistant phenotype of HeLa cells and an augmented cytotoxicity towards the platinum compound upon CUL4A downregulation. Taken together, our study underscores CUL4A as a cervical cancer oncogene and illustrates its potential as a prognosis indicator. Our investigation provides a novel avenue in improving current anti-cervical cancer therapy and overcoming the bottle-neck of Cisplatin resistance.
The dose of phentolamine will be 0.95 μg/kg•min, which will provide a total dose of 0.20 mg/kg. It will be administered 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp.
According to an embodiment of the present invention, a diagnostic system comprises: a user terminal for captures an image; and a server for obtaining diagnosis auxiliary information based on the image. The user terminal obtain a first photography variable by analyzing the image by a first image analysis algorithm, determines whether the first photography variable satisfies a pre-stored condition, and transmits the captured image to the server. The server obtains a first verification variable by analyzing the captured image by a second image analysis algorithm, determines whether to use the captured image as a diagnostic image based on the first verification variable, and obtains diagnostic auxiliary information by using the received image when the use is determined. The first image analysis algorithm and the second image analysis algorithm are different algorithms. The first image analysis algorithm and the second image analysis algorithm output analysis values related to an examination object. The examination object is a body part associated with a target disease for obtaining the diagnosis auxiliary information. Therefore, the present invention can provide an image verifying method for verifying images and using appropriate images as diagnostic images.
A yoga program adapted for those with PD will be used in the current study. It will be conducted over a 16-week period and consists of twice-weekly sessions lasting approximately one hour. The program will be based on principles of Hatha yoga which incorporate longer holds and deep breathing. Each session will include a warm-up, three yoga flows, a balance training section, and a cooldown phase. The first four weeks will emphasize proper alignment, breathing, and technique. Additionally, the classes will be led by a certified yoga instructor and include multiple on-site assistants to ensure a safe training environment. Participants will also be provided with assistive devices (i.e. chairs, yoga blocks, and blankets) if they are required.
The "MUSEUM" trial is a single-center, prospective, parallel-group, double-blind, randomized, controlled study design. The trial will be conducted at the Intensive Care Unit of the Puerto Rico Trauma Hospital located in San Juan, Puerto Rico. Patients with clinical and microbiological evidence of an Multi-drug resistant infection related to Hospital-acquired pneumonia (HAP), Ventilator-associated pneumonia (VAP), Complicated Urinary tract infection (cUTI) or Bloodstream infection (BSI) will be considered candidates for the study. The pathogen should be resistant to all antibiotics except to polymyxin B. With a predicted survival rate of 67% (hazard ratio of 0.33), a significance of α = 0.05, power of 80%, and assuming a dropout rate of 15%, the estimated sample size is n = 40 patients (20 per group). In terms of safety, the most clinically relevant adverse effects are nephrotoxicity and neurotoxicity, which will be evaluated and adjudicated. The recurrence of infection will be defined as a new superinfection by the same or other species than the initial infection that is multidrug-resistant. Length of stay at the Hospital will be measured from the day of admission until the day of discharge. Length of stay in the ICU will be measured from the day of admission until the day of discharge from the unit. To our knowledge, this will be the first prospective, double blind, randomized, controlled clinical trial in representation of the critically ill trauma patients infected with Multi-drug resistant pathogens.
1,149,366. Ketones. BOEHRINGER INGELHEIM G.m.b.H. 26 May, 1966 [28 May, 1965], No. 23716/66. Heading C2C. Novel ketones of the general formula wherein R 1  represents a hydrogen atom or an alkyl group containing 1 to 4 carbon atoms, R 2  represents a hydrogen atom or a straight chain or branched alkyl group containing 1 to 6 carbon atoms and amine represents an unsubstituted or alkyl-substituted pyrrolidino or morpholino group, and non-toxic acid addition salts thereof, are prepared: (a) by the reaction of a halogenoketone of the general formula wherein Hal represents a halogen atom, with unsubstituted or an alkyl-substituted pyrrolidine or morpholine; (b) by the reaction of a nitrile of the general formula with methylenedioxybenzene, preferably in the presence of a Friedel-Crafts catalyst, followed by hydrolysis of the resulting ketimine; (c) by the reaction of an acid amide or nitrile of the general formula wherein Z represents a free or substituted carboxamido group or a nitrile group, with an organo-magnesium compound of the general formula followed by decomposition of the resulting organometallic complex by hydrolysis; (d) by the reaction of an α-aminoalkanol of the general formula with an oxidizing agent, preferably chromic acid or an alkali metal dichromate, serving to oxidize the secondary alcohol group to a carbonyl group; and (e) by the reaction of an epoxy ether of the general formula wherein Alkyl represents an alkyl group with 1 to 4 carbon atoms, obtained by reaction of the halogenoketones of the second general formula with alkali metal alkoxides, with unsubstituted or an alkyl-substituted pyrrolidine or morpholine; followed in any of the above methods by optional conversion to a non-toxic acid addition salt of the product. Specification 927,475 is referred to. Pharmaceutical preparations comprising at least one ketone of the first general formula above as active ingredient in association with a pharmaceutical carrier, have a strong stimulating effect on the central nervous system, coupled with low toxicity, and may be administered orally or parenterally.
The objective of this randomized clinical trial is to develop low-cost hybrid remotely monitored parent-mediated multidisciplinary early intervention (EI) protocols for infants with CHD in Brazil. The protocols will be conducted via parents at home according to age modules (0- 3m, 3-6m, 6-9m, and 9-12m), and families will be monitored by clinical researchers weekly. High risk infants will receive supplemental EI services at the clinic according to developmental needs. Infants will receive outcome evaluations within a 42-month follow-up clinic. The aim of this study is to prevent or reduce neurodevelopmental sequelae and developmental delays associated with CHD. Participants in the intervention group receive multidisciplinary EIs in Nutrition (including breastfeeding support), Speech and Language Therapy for tube feeding transition, feeding readiness, and language and motor development and early stimulation for global development in cognitive, language and motor skills according to age milestones. Premature infants will receive age-corrected protocols and evaluations. Caregivers will receive psychological and protocol administration support. The control group receives basic child development, nutrition, and breastfeeding information provided by the Brazilian Ministry of Health, in addition to standard of care cardiac pediatric follow-up visits. Neurodevelopment is assessed with the Brazilian Version of Bayley Developmental Scale for Infants and Toddlers (3rd edition) in both groups, at 6, 12, 24, and 36-42 months. Nutritional outcomes, such as ml of breastmilk drown by mothers, and infant weight and length are measured. The study will compare the developmental outcome scores and parental quality of life scores of the intervention and control groups during the intervention (6 and 12months) and at 1 and 2 years follow up. We believe that infants with CHD who receive monitoring and early multidisciplinary interventions in the first year of life have better neurodevelopmental outcomes than infants who do not receive early multidisciplinary care. In Brazil, access to EI services is extremely limited to urban centers and higher income families. Infants from low-income backgrounds and rural settings are likely to be left without services during early childhood. Our remote, low-cost intervention aims at increasing access to EI for Brazilian infants with CHD.
Participants have received ASP1948 2000 mg intravenously, on day 1 of Q2W cycle for a period of up to 24 cycles or until a discontinuation criterion is met during treatment period. Qualifying participants have entered a re-treatment period and have received treatment for an additional 24 cycles or until a discontinuation criteria is met.
In ultrasound-guided pericapsular nerve group block Group , the patient will be positioned in a supine position. The anatomical landmarks, including ilio-pubic eminence, the iliopsoas muscle and tendon, the femoral artery and vein, and the pectineus muscle, will be identified using a 9-12 MHz superficial linear transducer. A lateral to medial in-plane technique will be used to insert a 22-gauge, 50-mm needle. the needle's tip will be positioned at the musculofascial plane, located between the ilio-pubic ramus posteriorly and the psoas tendon anteriorly. Following negative aspiration to avoid intravascular injection, 0.5-1 ml of normal saline will be injected to confirm the correct needle site. A 0.5 ml/kg plain bupivacaine 0.25% will be injected.
A home health monitoring system incorporates thermal cameras as detectors, enabling real-time monitoring and analysis of thermal data. The system monitors the activities and well-being of individuals or pets within its field of view. By detecting anomalies such as sudden falls, collapses, or medical emergencies through the identification of variations in body temperature or thermal patterns, the system can extract valuable insights about the activities and overall health of the monitored individuals or pets. It provides a comprehensive solution for real-time monitoring and analysis of thermal data. This information serves as the basis for generating timely reports, which are shared with nearby help centers to ensure swift and appropriate responses in emergencies. The integration of thermal imaging technology significantly enhances the effectiveness and accuracy of the home health monitoring system, thereby facilitating improved care and intervention for the monitored individuals or pets.
Mycobacteria, including Mycobacterium tuberculosis (Mtb) and non-tuberculous mycobacteria (NTM), pose challenges in treatment due to their increased resistance to antibiotics. Following infection, mycobacteria and their components trigger robust innate and inflammatory immune responses intricately associated with the modulation of mitochondrial functions, including oxidative phosphorylation (OXPHOS) and metabolism. Certainly, mitochondrial reactive oxygen species (mtROS) are an inevitable by-product of OXPHOS and function as a bactericidal weapon; however, an excessive accumulation of mtROS are linked to pathological inflammation and necroptotic cell death during mycobacterial infection. Despite previous studies outlining various host pathways involved in regulating mtROS levels during antimicrobial responses in mycobacterial infection, our understanding of the precise mechanisms orchestrating the fine regulation of this response remains limited. Emerging evidence suggests that mycobacterial proteins play a role in targeting the mitochondria of the host, indicating the potential influence of microbial factors on mitochondrial functions within host cells. In this review, we provide an overview of how both host and Mtb factors influence mtROS generation during infection. A comprehensive study of host and microbial factors that target mtROS will shed light on innovative approaches for effectively managing drug-resistant mycobacterial infections.
Method for determining the dose of at least one active agent based on a genetic analysis. The method comprises analyzing specific genes for their nucleotide sequence or their expression levels of gene-specific proteins and/or RNA molecules. The gene-specific data is assigned one or more relevant physiological functions of the human or animal body, in particular those which have an influence on the metabolism, absorption, excretion or distribution of the active agent in the body. The gene-specific data and the assigned physiological functions are then integrated into a physiology-based pharmacokinetic model (PBPK model). The PBPK model integrates pharmacokinetic data relating to one or more active agents. The PBPK model may also receive and evaluate patient-specific data directly inputted and combined with data from a knowledge database comprising known values of pharmacokinetic parameters. The PBPK's integration of these data provide a calculation of the individual dose of the active agent.
OBJECTIVES: Tinnitus subtypes are proposed to lie on a continuum of different symptom dimensions rather than be categorical. However, there is no comprehensive empirical data showing this complex relationship between different tinnitus symptoms. The objective of this study is to provide empirical evidence for the dimensional nature of tinnitus and how different auditory and non-auditory symptoms interact with each other through complex interactions. We do this using graph theory, a mathematical tool that empirically maps this complex interaction. This way, graph theory can be utilised to highlight a new and possibly important outlook on how we can understand the heterogeneous nature of tinnitus.
DESIGN: In the current study, we use the screening databases of the Treatment Evaluation of Neuromodulation for Tinnitus-Stage A1 (TENT-A1) and A2 (TENT-A2) randomised trials to delineate the dimensional relationship between different clinical measures of tinnitus as a secondary data analysis. We first calculate the empirical relationship by computing the partial correlation. Following this, we use different measures of centrality to describe the contribution of different clinical measures to the overall network. We also calculate the stability of the network and compare the similarity and differences between TENT-A1 and TENT-A2.
RESULTS: Components of the auditory subnetwork (loudness discomfort level, sound sensitivity, average hearing loss and high frequency hearing loss) are highly inter-connected in both networks with sound sensitivity and loudness discomfort level being highly influential with high measures of centrality. Furthermore, the relationship between the densely connected auditory subnetwork with tinnitus-related distress seems to vary at different levels of distress, hearing loss, duration and age of the participants.
CONCLUSION: Our findings provide first-time evidence for tinnitus varying in a dimensional fashion illustrating the heterogeneity of this phantom percept and its ability to be perceptually integrated, yet behaviourally segregated on different symptomatic dimensions.
FIELD: genetic engineering, molecular biology. SUBSTANCE: invention can be used in medico-biological industry for preparing medicinal agents for genetic therapy. Invention reports about preparing and characterizing the sequence of human endoglyne gene promoter displaying high specificity with respect to endothelium tissue. Also, fragments of indicates sequence are determined that retain ability to carry out the function of full-sized promoter. Invention proposes nucleotide constructions where gene(s) is located being them transcription is to be activated desirably and this gene is located under control of a new promoter or its active fragment. Medicinal agents used for treatment of many human diseases can be prepared by insertion of proposed constructions into suitable vectors. EFFECT: valuable biological and medicinal properties of gene promoter. 12 cl, 5 dwg, 1 tbl, 1 ex
Potential participants will be recruited at study sites where they are admitted/held for COVID-19 isolation. On the first day of isolation (ideally on the day they first test positive for SARS-CoV-2), potential participants will be asked to participate in the study. After consent (Study Day 0), two nasopharyngeal swabs (NP swabs) and one nasal swab will be collected. One NP swab will be tested via viral culture and the other nasal swab will be tested by RT-PCR for SARS-CoV-2. The nasal swab will be tested on the BD Veritor System. Specimen collection and testing will be repeated every 2 days for 6 days (Study Day 2, Day 4, and Day 6) or until the RT-PCR Ct value is \>30, whichever comes first. Participants will be monitored for symptoms of COVID-19 throughout the study.
IXINITY [coagulation factor IX (recombinant)] is a purified protein that has 415 amino acids. It has an amino acid sequence that is comparable to the Thr148 allelic form of plasma-derived factor IX. Coagulation factor IX (recombinant) is a single-chain glycoprotein with a molecular mass of about 55,000 Dalton that is secreted by a genetically engineered mammalian cell line derived from Chinese hamster ovary (CHO) cells. No human or animal proteins are added during any stage of manufacturing or formulation of IXINITY. The CHO cell line secretes recombinant factor IX into a defined cell culture medium that does not contain hormones. The recombinant factor IX is purified by a chromatography purification process. The process includes three validated steps for virus inactivation and removal, namely, solvent/detergent treatment, a chromatographic step, and nanofiltration. The process also includes a validated step to reduce the presence of CHO proteins in the final drug product.

IXINITY is formulated as a sterile, nonpyrogenic lyophilized powder to be reconstituted with Sterile Water for Injection for intravenous administration. It does not contain any preservatives and is available in single-dose vials containing the labeled amount of factor IX activity, expressed in international units (IU). Each vial contains nominally 250, 500, 1000, 1500, 2000, or 3000 IU of recombinant coagulation factor IX. After reconstitution of the lyophilized powder, all dosage strengths yield a clear, colorless solution. The concentrations of excipients are:
PURPOSE:To obtain a nonpoisonous dental metallic material having a low m.p. used after mixing and kneading with metallic powder by specifying the composition of a multicomponent alloy consisting of In, Sn, Ga and Ag, Al, Zn, Au or Cu. CONSTITUTION:This dental metallic material used after mixing and kneading with metallic powder is a quaternary or higher multicomponent alloy having <=15 deg.Cm.p. and consisting of 1-45wt% In, 1-30wt% Sn, 0.5-25wt% one or more among Ag, Al, Zn, Au and Cu, and the balance Ga. The material shows no poisonous character and has a great affinity for other metal. The corrosion resistance and mechanical characteristics can be improved by adding various metals. The material has a superior wetting property to dentin and other metal, so when a tooth is filled with the material, no gap is left in the dentin, and the material is used with very high work efficiency because of its low m.p.
Diabetes, especially type 2 diabetes (T2D), poses an unprecedented challenge to global public health. Hydration status also plays a fundamental role in human health, especially in people with T2D, which is often overlooked. This study aimed to explore the longitudinal associations between hydration status and the risk of T2D among the Chinese population. This study used data from the large community-based Kailuan cohort, which included adults who attended physical examinations from 2006 to 2007 and were followed until 2020. A total of 71,526 participants who eventually met the standards were divided into five hydration-status groups based on their levels of urine specific gravity (USG). Multivariable and time-dependent Cox proportional hazards models were employed to evaluate the associations of baseline and time-dependent hydration status with T2D incidence. Restricted cubic splines (RCS) analysis was used to examine the dose-response relationship between hydration status and the risk of T2D. Over a median 12.22-year follow-up time, 11,804 of the participants developed T2D. Compared with the optimal hydration-status group, participants with dehydration and severe dehydration had a significantly increased risk of diabetes, with adjusted hazard ratios (95% CI) of 1.30 (1.04-1.63) and 1.38 (1.10-1.74). Time-dependent analyses further confirmed the adverse effects of impending dehydration, dehydration, and severe dehydration on T2D incidence by 16%, 26%, and 33% compared with the reference group. Inadequate hydration is significantly associated with increased risks of T2D among Chinese adults. Our findings provided new epidemiological evidence and highlighted the potential role of adequate hydration status in the early prevention of T2D development.
Allantoin-containing preparations are prepared in a form suitable for administration as gels and aerosols. In one embodiment of the aerosol formulation, an allantoin-containing composition comprises: (1) water; (2) allantoin in a therapeutically effective quantity; (3) an anionic ethoxylated surfactant; (4) lanolin oil; and (5) cod liver oil. The composition has a viscosity and surface tension in a range that allows the composition to be administered to the skin of a user as an aerosol by a mechanical spray pump. In another aspect of this invention, the allantoin-containing preparations are prepared in a form suitable for administration as gels. The compositions can be substantially anhydrous or can contain water. In one embodiment of the gel formation, an allantoin-containing composition comprises: (1) allantoin in a therapeutically effective quantity; (2) a complex comprising mineral oil and at least one hydrogenated alkylene copolymer; (3) lanolin oil; and (4) cod liver oil. The compositions can comprise other ingredients. Compositions according to the present invention are suitable for the treatment of a number of skin conditions or diseases characterized by ulceration, inflammation, or blistering of the skin, such as epidermolysis bullosa.